GERON CORP APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
GERON CORP (GERN) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $4.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-08-05
- GERON CORP apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $4.93M, a 26.79% decline year-over-year.
- GERON CORP apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-03-31 was $4.90M, a 33.86% decline year-over-year.
- GERON CORP apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-06-30 was $6.74M.
- GERON CORP apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-03-31 was $7.41M.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month |
|---|---|---|
| 2026-06-30 | $4.93M 10-Q · filed 2026-08-05 | $9.83M derived: sum of 2 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.90M 10-Q · filed 2026-08-05 | |
| 2025-06-30 | $6.74M 10-Q · filed 2026-08-05 | $14.15M derived: sum of 2 quarters · filed 2026-08-05 |
| 2025-03-31 | $7.41M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |